Insider buying last 90 days
$990Kin 1 open-market purchase
| Filed | Insider | Type | Value |
|---|---|---|---|
| Jul 13 | Jon Halbert Director | Purchase | $990K |
From Form 4 filings, dated to when each was filed.
NASDAQ: CAI
Caris Life Sciences (CAI) Stock Analysis & Forecast
Sep 28 close
$31.75−0.23 (−0.7%)
Gekko Brief
AI summaryThis week's coverage of Caris Life Sciences (CAI) centers on analyst sentiment and an insider stock sale notice. Thirteen research firms hold an average "Hold" recommendation with a 12-month price target of $26.50, below the recent share price of $31.47. Separately, officer John Russel Denton filed a Rule 144 notice to sell 7,500 common shares valued at $238,626.00, shares acquired privately in June 2025.
CAI closed at $31.75, down 0.7%, sitting above both its 50-day average of $23.32 and 200-day average of $21.15, with the shorter average above the longer one. The stock's one-month return stands at 20.4% and its three-month return at 73.3%, with the 52-week range spanning $14.19 to $33.65. The GekkoIndex reads 46.5, placing CAI in the Neutral zone, up 4.3 over five sessions. Price sits 25.7% above the Gekko Fair Value of $25.25.
The next earnings report is scheduled for 4 November 2026 after close, 36 days out and beyond a typical 20-trading-day holding window. The last report, on 5 August 2026, brought a 24.2% reaction, part of a pattern including five beats across eight quarters and an average absolute reaction of 16.9%. Smart money activity in the last 90 days includes one open-market insider purchase valued at $990,080.00, alongside 2 billionaire holders. Analyst coverage shows 9 firms with 6 buy and 3 hold ratings, a consensus target of $28.15.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Caris Life Sciences price vs fair value
Close $31.75200-day averageGekko Fair Value $25.25
Caris Life Sciences quick facts
- Market cap
- $8.98B
- P/E ratio
- 3.3
- Forward P/E
- 43.3
- EPS, TTM
- $9.58
- Revenue, TTM
- $989.6M
- Profit margin
- 10.6%
- Dividend yield
- —
- Beta
- —
- Volume
- 3.92M avg 5.31M
- 1-year return
- +6.8%
- Typical daily move
- ±4.9%
- Typical 20-day move
- ±12.5%
- 50-day average
- $23.32
- 200-day average
- $21.15
- Next earnings
- Nov 4 after close
- Shares outstanding
- 282.7M
Caris Life Sciences swing-trade checklist
Caris Life Sciences scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $31.75 is above the 50-day ($23.32) and 200-day ($21.15) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
46.5, Neutral
Reading 46.5 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
25.7% above
Price is 25.7% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: 1 open-market insider purchase.
See smart money - Earnings risksupportive
Reports in 36 days
Next report Nov 4, 2026, 36 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityno data
No data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
Caris Life Sciences stock chart and price history
Caris Life Sciences closed at $31.75 on Sep 28, 2026, +6.8% over the past year, inside a 52-week range of $14.19 to $33.65.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +20.4%
- 3 months
- +73.3%
- 6 months
- +87.3%
- 1 year
- +6.8%
The full CAI chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open CAI in Gekko
Follow Caris Life Sciences through every session
Put CAI on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track CAI in GekkoFree for 7 days. No credit card required.
About Caris Life Sciences
Caris Life Sciences applies artificial intelligence to molecular profiling, giving clients in the United States and abroad detailed analysis of disease at the molecular level. It is known for tools that examine tissue and blood samples to inform cancer-related medical decisions, combining large sets of molecular data with machine learning to guide treatment choices.
Its offerings include MI Profile, which studies tissue samples, and Caris Assure, a blood-based test used in cancer care. Beyond these diagnostic products, the company works with biopharmaceutical firms, supporting their research and development through laboratory services, data analysis, and collaborative research projects.
Caris Life Sciences was founded in 2008 and is headquartered in Irving, Texas. Its shares are listed on the NASDAQ under the ticker CAI.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- carislifesciences.com
Caris Life Sciences GekkoIndex: the smart money zone
Caris Life Sciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 46.5, in the Neutral zone, up 4.3 points over five sessions.
46.5Neutral
Up 4.3 points over five sessions, from the Distribution zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 33 | +1.3% | +5.0% | ||
| Accumulation | 122 | −0.4% | +2.4% | ||
| Neutral (current zone) | 144 | +1.5% | −0.5% | ||
| Distribution | 14 | +1.5% | +11.5% | ||
| Selling | 2 | Too few readings yet | |||
Average CAI share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the CAI price, zone by zone.Track CAI in Gekko
Is Caris Life Sciences stock overvalued? Gekko Fair Value
Caris Life Sciences trades 25.7% above Gekko Fair Value of $25.25, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Caris Life Sciences shares are worth, recalculated every trading day.
$25.25
Gekko Fair Value, Sep 29, 2026
25.7% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open CAI in Gekko
Caris Life Sciences insider and Congress trading
Insiders filed 1 open-market purchase in Caris Life Sciences worth $990K, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in CAI were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for CAI, plotted on the chart in Gekko.Open CAI in Gekko
Buybacks
Caris Life Sciences has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $21.36M
- As a share of market cap
- 0.24%
From company filings.
Hedge funds and billionaires quarter ended Mar 31
2of the funds Gekko tracks hold CAI.
0added1opened1trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Caris Life Sciences earnings: next date and track record
Caris Life Sciences reports on Nov 4, 2026, after the close (36 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected after the close, 36 days away
- EPS estimate
- $0.03
- Revenue estimate
- $256.3M
5 of 8reports beat the EPS estimate
±16.9%average move across the report
3 of 5reports followed by a gain
Share-price move across each report
Last earnings call, Aug 5, 2026 AI summary
- What they said
- Caris Life Sciences reported a record Q2 2026 with 59,200 cases, adding ~6,400 sequentially. Over 345,000 clinical oncology tests were run, including 114,000+ Whole Exome and Transcriptome tests. The company highlighted its 1.13 million patient molecular database, AI assistant 'JAKE,' and launched Caris Detect, a multi-cancer early detection test covering 58 cancer types using Whole Genome and Transcriptome Sequencing.
- Guidance
- Management indicated near-term demand for Caris Detect may outpace rollout capacity, with potential back orders during scaling. Commercial investments from Q1 are expected to continue driving volume growth into H2 2026. No specific revenue or EPS targets were provided in this excerpt.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $0.00 est $0.01 | $263.7M est $238.1M | +24.2% |
| May 7, 2026 | $0.00 est −$0.02 | $216.2M est $209.4M | −15.6% |
| Feb 26, 2026 | $0.28 est $0.10 | $292.9M est $240.4M | +10.0% |
| Nov 5, 2025 | $0.08 est −$0.08 | $216.8M est $280.9M | −21.1% |
| Aug 12, 2025 | −$0.54 est −$0.21 | $181.4M est $137.7M | +13.5% |
| Jun 9, 2025 | −$0.35 est −$0.22 | $120.9M est $138.0M | — |
| Nov 5, 2021 | $2.95 est $0.61 | $100.8M est $90.24M | — |
| Aug 3, 2021 | $2.20 est $1.20 | $85.70M est $90.23M | — |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Caris Life Sciences stock forecast and analyst price targets
Analysts’ average 12-month price target for Caris Life Sciences is $28.15, −11.3% from the last close, from 9 firms rating the stock in the last 90 days.
$28.15consensus 12-month target, −11.3% from the last close
Now $31.75Avg $28.15
Low $21High $32
Each firm’s latest rating in the last 90 days: 9 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 9 | UBS | $28 | −11.8% |
| Aug 6 | Bank of America Securities | — | — |
| Aug 6 | J.P. Morgan | $25 | −21.3% |
| Aug 6 | Evercore ISI | $26 | −18.1% |
| Aug 6 | Piper Sandler | $21 | −33.9% |
−0.5%average 20-day move after past Neutral readings
±4.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Caris Life Sciences market cap and key statistics
Caris Life Sciences’s market cap is $8.98B, with a P/E ratio of 3.3 and revenue of $989.6M over the last twelve months.
Valuation
- Market cap
- $8.98B
- P/E ratio
- 3.3
- Forward P/E
- 43.3
- EPS, TTM
- $9.58
- Gekko Fair Value
- $25.25
Trading
- Volume
- 3.92M
- Avg volume, 20 days
- 5.31M
- 52-week high
- $33.65
- 52-week low
- $14.19
- Shares outstanding
- 282.7M
Financials
- Revenue, TTM
- $989.6M
- Profit margin
- 10.6%
- Return on equity
- 20.1%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Typical daily move
- ±4.9%
- Typical 20-day move
- ±12.5%
Caris Life Sciences stock news this week
Coverage of Caris Life Sciences this week reads neutral: 0 positive, 3 neutral and 0 negative headlines.
Caris Life Sciences peers
Caris Life Sciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 24.4% below |
| GILDGilead Sciences | Neutral | 6.9% above |
| MRNAModerna | Neutral | 73.2% above |
| NTRANatera | Distribution | 25.1% above |
| IQVIQVIA | Neutral | 14.2% above |
| UTHRUnited Therapeutics | Accumulation | 23.6% below |
A peer links to its own page where one exists.
Caris Life Sciences stock FAQ
What is Caris Life Sciences’s market cap?
Caris Life Sciences’s market cap is $8.98B at the Sep 28, 2026 close of $31.75, with 282.7M shares outstanding. The shares trade on a P/E ratio of 3.3.
What is the Caris Life Sciences stock forecast?
The consensus analyst 12-month price target for Caris Life Sciences is $28.15, −11.3% from the last close. Of the 9 firms that rated the stock in the last 90 days, 6 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Caris Life Sciences stock overvalued or undervalued?
On Gekko’s estimate Caris Life Sciences is overvalued: the Sep 28, 2026 close of $31.75 is 25.7% above Gekko Fair Value of $25.25. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Caris Life Sciences report earnings next?
Caris Life Sciences is expected to report on Nov 4, 2026, after the market closes (36 days away). Analysts expect earnings of $0.03 per share on revenue of $256.3M. Caris Life Sciences beat the earnings estimate in 5 of its last 8 reports, moving 16.9% on average across the report.
What is Caris Life Sciences’s 52-week high and low?
Caris Life Sciences’s 52-week high is $33.65 and its 52-week low is $14.19; it closed at $31.75 on Sep 28, 2026, +6.8% over the past year. Over the last five years the shares peaked at $42.50 on Aug 22, 2025.
Is Caris Life Sciences stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, smart money and earnings risk), 1 as mixed (gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Caris Life Sciences the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.